Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results

by · The Markets Daily

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10, FiscalAI reports. The company had revenue of $37.76 million for the quarter, compared to analyst estimates of $37.08 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%.

Here are the key takeaways from Zevra Therapeutics’ conference call:

  • MIPLYFFA sales accelerated: Third-quarter revenue rose 45% year over year to $37.8 million, including $34 million in U.S. MIPLYFFA sales, which increased 12.6% from Q2. The company reported 197 cumulative prescription enrollment forms, 69% payer coverage, and strong refill and retention rates.
  • Zevra believes the U.S. NPC market may be larger than its original estimate of 300–350 diagnosed patients, citing a steady flow of newly diagnosed patients and claims-data analysis. It modestly expanded its commercial team and plans to submit an sNDA in the first quarter of 2027 to potentially include patients younger than 24 months.
  • The European review of arimoclomol is ongoing, with an expert group and the CHMP expected to evaluate the data; Zevra continues to expect a CHMP opinion in the fourth quarter. The outcome remains a significant regulatory uncertainty for expanding MIPLYFFA access in Europe.
  • Zevra ended the quarter with $270.9 million in cash, cash equivalents, and investments, up $10.7 million sequentially, and reported net income of $19.2 million. The company said its balance sheet provides flexibility to expand MIPLYFFA access and advance its pipeline, including the 72-patient celiprolol DiSCOVER trial, which has recorded four confirmed events to date.

Zevra Therapeutics Price Performance

ZVRA stock traded up $0.16 during mid-day trading on Tuesday, reaching $10.26. The company had a trading volume of 688,233 shares, compared to its average volume of 1,217,035. The company has a market capitalization of $609.28 million, a price-to-earnings ratio of 11.15 and a beta of 0.98. Zevra Therapeutics has a 52 week low of $8.01 and a 52 week high of $15.03. The stock has a 50 day simple moving average of $11.14 and a two-hundred day simple moving average of $10.74.

Insider Buying and Selling at Zevra Therapeutics

In related news, CEO Neil McFarlane sold 20,000 shares of the business’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $11.25, for a total transaction of $225,000.00. Following the transaction, the chief executive officer directly owned 417,225 shares in the company, valued at approximately $4,693,781.25. The trade was a 4.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $11.25, for a total transaction of $138,375.00. Following the sale, the director directly owned 1,800 shares in the company, valued at $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ZVRA has been the topic of several research reports. HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of Zevra Therapeutics in a research note on Thursday, August 20th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. Guggenheim lowered their price objective on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Finally, BTIG Research cut their price objective on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.14.

Read Our Latest Research Report on ZVRA

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.

Read More